Espacio destinado a hablar desde la evidencia médica, lo actual y de importancia respecto a esta enfermedad.
Hablemos de COVID-19
Claim This Podcastby Jonathan Francisco Barrera Jerez
5 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇨🇴
Podcast Overview
Espacio destinado a hablar desde la evidencia médica, lo actual y de importancia respecto a esta enfermedad.
Language
🇪🇸
Publishing Since
4/17/2021
1 verified contact email on file for Hablemos de COVID-19
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
October 5, 2021
Episodio 05 - Futuro y COVID-19
<p>Hablemos del futuro predicible que tenemos para COVID-19. </p> <p><br></p> <p>Referencias:</p> <p>1.Schmitt, J., Wang, J. Quantitative modeling of the impact of facemasks and associated leakage on the airborne transmission of SARS-CoV-2. Sci Rep 11, 19403 (2021). https://doi.org/10.1038/s41598-021-98895-9.</p> <p>2. Spang, R.P., Pieper, K. The tiny effects of respiratory masks on physiological, subjective, and behavioral measures under mental load in a randomized controlled trial. Sci Rep 11, 19601 (2021). https://doi.org/10.1038/s41598-021-99100-7.</p> <p>3. Blanken, T.F., Tanis, C.C., Nauta, F.H. et al. Promoting physical distancing during COVID-19: a systematic approach to compare behavioral interventions. Sci Rep 11, 19463 (2021). https://doi.org/10.1038/s41598-021-98964-z.</p> <p>4. Du, W., Iacoviello, F., Fernandez, T. et al. Microstructure analysis and image-based modelling of face masks for COVID-19 virus protection. Commun Mater 2, 69 (2021). https://doi.org/10.1038/s43246-021-00160-z.</p> <p>5. Pardo, Carlos Felipe, Zapata-Bedoya, Silvana, Ramirez-Varela, Andrea, Ramirez-Corrales, Daniel, Espinosa-Oviedo, Jairo-José, Hidalgo, Darío, Rojas, Nestor, González-Uribe, Catalina, García, Juan David, & Cucunubá, Zulma M.. (2021). COVID-19 and public transport: an overview and recommendations applicable to Latin America. Infectio, 25(3), 182-188. Epub May 15, 2021.https://doi.org/10.22354/in.v25i3.944.</p> <p>6. Wang, B., et al. 2021. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. The lancet. VOLUME 15, 100276.</p> <p>7. Thomas, J, S., et al. 2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. NEJM. DOI: 10.1056/NEJMoa2110345</p> <p><br></p> <p>Música:</p> <p>Cheel: </p> <p>https://soundcloud.com/cheel</p> <p>Music promoted by @RFM - Royalty Free Music [No Copyright Music]: https://youtu.be/YPXlTYa5fYU</p> <p><br></p>
September 1, 2021
Episodio 04 - Resumen mes de Agosto 2021.
<p>Hoy hablaremos de lo más relevante para COVID-19 en el mes de Agosto.</p> <p>REREFENCIAS:</p> <p>1. Drakos, S., Chatzantonis, G., Bietenbeck, M. et al. A cardiovascular magnetic resonance imaging-based pilot study to assess coronary microvascular disease in COVID-19 patients. Sci Rep <strong>11, </strong>15667 (2021). <a href="https://doi.org/10.1038/s41598-021-95277-z">https://doi.org/10.1038/s41598-021-95277-z</a> (1:55 – 4.25 min)</p> <p>2. Katsoularis, I., et al. 2021. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. THE LANCET. DOI:https://doi.org/10.1016/S0140-6736(21)00896-5. (5:16 – 9:37 min)</p> <p>3. Petherick, A., Goldszmidt, R., Andrade, E.B. et al. A worldwide assessment of changes in adherence to COVID-19 protective behaviours and hypothesized pandemic fatigue. Nat Hum Behav (2021). <a href="https://doi.org/10.1038/s41562-021-01181-x">https://doi.org/10.1038/s41562-021-01181-x</a>(9:39 - 11:12 min)</p> <p>4. Sankary, K.M., Sippel, J.L., Eberhart, A.C. et al. Breakthrough cases of COVID-19 in vaccinated United States Veterans with spinal cord injuries and disorders. Spinal Cord (2021). <a href="https://doi.org/10.1038/s41393-021-00690-w">https://doi.org/10.1038/s41393-021-00690-w</a>(11:16 -15:33 min)</p> <p>5. Sanderson, K. 2021. COVID vaccines protect against Delta, but their effectiveness wanes. Nature. <a href="https://doi.org/10.1038/d41586-021-02261-8">https://doi.org/10.1038/d41586-021-02261-8</a>(15:34 - 16:47 min)</p> <p>6. Korley, F. K. et al. 2021. Early Convalescent Plasma for High-Risk Outpatients with Covid-19. NEJM. DOI: 10.1056/NEJMoa2103784 (16:48 – 18:20 min)</p> <p>7. Hammerschmidt, S.I., Bosnjak, B., Bernhardt, G. et al. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol (2021). <a href="https://doi.org/10.1038/s41423-021-00755-z">https://doi.org/10.1038/s41423-021-00755-z</a>(18:21 -20:31 min)</p> <p>8. Koopmans., M. et al. 2021.Origins of SARS-CoV-2: window is closing for key scientific studies. Nature. 596, 482-485. doi: <a href="https://doi.org/10.1038/d41586-021-02263-6">https://doi.org/10.1038/d41586-021-02263-6</a>(20:31 - 23:17)</p> <p>9. Barda, N., et al. 2021. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. NEJM. DOI: 10.1056/NEJMoa2110475 (23:18 – 26:50 min)</p> <p>Uso de música:</p> <p>Road Trip by Pyrosion https://soundcloud.com/pyrosion</p> <p>Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0</p> <p>https://creativecommons.org/licenses/...</p> <p>Música promovida por: Sound Machine Channel</p> <p>https://www.youtube.com/c/soundmachin...</p>
May 7, 2021
Episodio 03 - Vacunas RNAm
<p>Hablemos un poco sobre las vacunas de RNAm respecto a lo que tenemos hoy en la evidencia, sobre su seguridad, poblaciones a vacunar y seguridad. </p> <p><br></p> <p>1. Polack, F., et al. 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. engl j med 383;27.</p> <p>2. Thompson MG. Et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3. PMID: 33793460.</p> <p>3. Britton, A.. Et al (2021). Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021. MMWR. Morbidity and mortality weekly report, 70(11), 396–401. https://doi.org/10.15585/mmwr.mm7011e3</p> <p>4. Shimabukuri, T.T. et al. 2021. Preliminary findings of mRNA Covid-19 Vaccine Safety in Pregnant persons. NEJM, April,DOI: 10.1056/NEJMoa2104983.</p> <p>5. Rinott, E., Youngster, I. y Lewis, YE (2021). Reduction in COVID-19 Patients Requiring Mechanical Ventilation Following Implementation of a National COVID-19 Vaccination Program — Israel, December 2020–February 2021. MMWR. Informe semanal de morbilidad y mortalidad , 70 (9), 326-328. https://doi.org/10.15585/mmwr.mm7009e3</p> <p>6. Haas, E, J. et al. 2021- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet, ISSN 0140-6736, https://doi.org/10.1016/S0140-6736(21)00947-8.</p> <p>7. Monin,. L. et al. 2021. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. April DOI:https://doi.org/10.1016/S1470-2045(21)00213-8.</p> <p>8. Baden,. L R. et al. 2020. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384: 403-416. DOI: 10.1056 / NEJMoa2035389.</p> <p>9. Remmel,. A. 2021. COVID vaccines and safety: what the research says. Nature, Disponible en: https://www.nature.com/articles/d41586-021-00290-x. Accesado el 04 de mayo del 2021. </p> <p>10. Tenforde MW, Olson SM, Self WH, et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021. MMWR Morb Mortal Wkly Rep. ePub: 28 April 2021. DOI: http://dx.doi.org/10.15585/mmwr.mm7018e1external.</p> <p>11. Baden LR. Et al. 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.</p> <p>12. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. PMID: 33629336.</p> <p>Link New York Times para Pfizer: https://www.nytimes.com/interactive/2020/health/pfizer-biontech-covid-19-vaccine.html</p> <p>Link New York times para Moderna: </p> <p>https://www.nytimes.com/interactive/2020/health/moderna-covid-19-vaccine.html</p> <p><br></p> <p>Derechos de música: </p> <p>"Scandinavianz - Breeze" is under a Creative Commons (CC BY 3.0) license.</p> <p>https://youtu.be/0GbM2rL0HCY<br> </p> <p>Music promoted by BreakingCopyright: https://youtu.be/0IkBSGqevFQ</p>
5 total episodes available
Deep-dive analytics for Hablemos de COVID-19
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Hablemos de COVID-19?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.